ITOCHU-CORPORATION
ITOCHU Corporation (headquartered in Minato-ku, Tokyo; Yoshihisa Suzuki, President & COO; hereinafter "ITOCHU") is displaying projection mapped images on the wall of its Tokyo Head Office for three days from Saturday, January 9 to Monday, January 11, 2021. (The display is also being livestreamed on YouTube.)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210109005017/en/
The COVID-19 pandemic that has continued causing distress since last year has not yet slowed. Given this situation, ITOCHU, a company that supports people's everyday lives, is delivering a message to the world in 21 languages, to reflect the year 2021, hoping to express shared wishes for a brighter and more promising new year with as many people as possible around the world.
Outline of the projection mapped display: |
|
Time and date: Saturday, January 9 to Monday, January 11, 2021 |
|
|
6PM to 6:40PM (JST) : ITOCHU's original contents (in 21 languages) |
|
6:40PM to 8PM (JST) : Public message on the COVID-19 disaster (in 4 languages) |
Venue: The images will be projected on the wall on the ITOCHU Garden side (Gaien Icho Namiki side) of ITOCHU’s Tokyo Head Office |
|
Livestream URL: Sunday, January 10 - https://youtu.be/dE2jTMoCQfk |
|
|
Monday, January 11 - https://youtu.be/-sNQFeiM0z4 |
The projection mapped display is being livestreamed on the following websites.
Official YouTube channel
https://youtu.be/ZzcEM2nPAkA
Official photo data URL:
https://drive.google.com/drive/folders/1qY7IM7U1Y71i91bF-Am43FAQWV-dqX8F
View source version on businesswire.com: https://www.businesswire.com/news/home/20210109005017/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SK pharmteco Boosts Domestic Peptide Scale-Up with Investment in California Facility23.10.2025 15:03:00 CEST | Press release
Expansion leverages proprietary chromatography expertise to overcome purification bottlenecks and secure domestic API manufacturing capacity SK pharmteco, a global contract development and manufacturing organization (CDMO), announced today a $6.1 million investment in its Rancho Cordova facility to expand and equip a new lab and CGMP-Kilo-scale facility for Solid-Phase Peptide Synthesis (SPPS) and purification. This expansion, combined with SK pharmteco’s industry-leading chromatography expertise and existing development and manufacturing capabilities in the United States, positions the company to meet the rising demand for U.S. peptide development and domestic clinical and commercial manufacturing. "The investment in our California facility represents a key milestone in our strategic growth and demonstrates an unwavering dedication to the domestic biopharma sector,” said Joerg Ahlgrimm, CEO of SK pharmteco. “Peptides are a vital and rapidly advancing therapeutic category. This project
Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference23.10.2025 15:00:00 CEST | Press release
- Data presented on outcomes following treatment with CFTR modulators add to growing body of evidence that reduced level of sweat chloride is associated with improved clinical outcomes, particularly in younger people with cystic fibrosis - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the clinical benefits of treatment with CFTR modulators, including the Company’s most recently approved medicine, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), at the North American Cystic Fibrosis Conference (NACFC) held from October 22-25 in Seattle, Washington. Several of the abstracts that will be presented at this year’s conference demonstrate that improvement in CFTR function, as measured by reduction in sweat chloride (SwCl), is associated with improved outcomes in people with cystic fibrosis (CF). ALYFTREK has shown greater reductions in sweat chloride compared to TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor
Boomi Recognized as an Exemplary Vendor in the ISG Buyers Guides™ for Data Integration and Master Data Management 202523.10.2025 15:00:00 CEST | Press release
Boomi earns top rankings across product capability, validation, and customer experience in dual Buyers Guides from ISG Software Research Boomi™, the leader in AI-driven automation, today announced it has been named an Exemplary Vendor in both the ISG Buyers Guide™ for Data Integration and the ISG Buyers Guide™ for Master Data Management 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023515342/en/ Boomi Recognized as an Exemplary Vendor in the ISG Buyers Guides™ for Data Integration and Master Data Management 2025 In these independently published reports from ISG Software Research, a division of ISG (Information Services Group), Boomi was recognized as a Leader across multiple evaluation dimensions, including Product Experience, Capability, Customer Experience, and Validation. Customer Experience and Validation The ISG Buyers Guide™ assessments are widely used by enterprise technology buyers to evaluate market-leadin
CWAN and J.P. Morgan Asset Management Launch Automated Cash Management Solution for Hedge Funds23.10.2025 15:00:00 CEST | Press release
New integration connects Enfusion by CWAN and Morgan Money® to optimize yield, diversification, and liquidity control for hedge fund clients Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, and J.P. Morgan Asset Management today announced an integration that transforms how hedge funds manage cash. The solution links Enfusion by CWAN directly with the Morgan Money® trading platform, J.P. Morgan Asset Management’s short-term investment management solution, giving clients a single, automated workflow for investing and monitoring idle cash. Through this connection, hedge funds can now: Maximize idle cash by automatically investing in a diversified range of money market funds. Reduce concentration risk by spreading cash across multiple managers, custodians, and currencies. Improve liquidity visibility through real-time data and automated withdrawal and deposit capabilities. Eliminate manual treasury work, freeing teams to focus on trad
Foresight Launches the First Conversational AI Interface to Query Unified Private Market Data23.10.2025 14:07:00 CEST | Press release
From deal sourcing to portfolio management, Foresight is shaping the future of how the private market engages with data Foresight is ushering in the next generation of private market software by letting its customers use natural language to query their unified pre- and post-deal data. Today, the company announced new AI capabilities that will give customers the ability to ask questions within the Foresight platform as well as in ChatGPT, Claude, and Glean through its new model context protocol (MCP) server. Private market dealmakers will be able to prompt Foresight’s AI for lists of prospective companies, and anyone who makes post-deal decisions will be able to ask portfolio questions, model scenarios, and execute workflows in natural language on Foresight’s desktop or mobile interfaces. “The $15 trillion private market has run on data silos and Excel, which has created unnecessary opacity. Foresight unlocks the data and analytics that fund managers and financial institutions need by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom